The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) conducted a comprehensive safety review in 20232024 examining reports of suicidal and self-injurious thoughts with GLP-1 receptor agonists used for both diabetes and weight management
Understanding your specific product type is essential for safe handling and administration
Large-scale real-world data and clinical trials indicate that GLP-1RAs reduce alcohol intake even among those without the explicit goal of quitting alcohol consumption (3)
~33.3% of users lost 10% or more body weight ~9.5% of users lost 15% or more body weight Common side effects Side effects include but are not limited to nausea, heartburn, hypoglycemia, constipation, and diarrhea, among others
Its value depends heavily on the formulation being used
The article says baseline gut microbiota composition, shaped in part by prior antibiotic use and dietary history, influences how the intestines respond to GLP-1 induced changes in motility